D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Microbiology D-index 65 Citations 13,037 216 World Ranking 813 National Ranking 19
Medicine D-index 80 Citations 20,486 335 World Ranking 9695 National Ranking 129

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Acquired immunodeficiency syndrome
  • Virus

José M. Gatell mainly investigates Internal medicine, Viral load, Immunology, Acquired immunodeficiency syndrome and Surgery. His work carried out in the field of Internal medicine brings together such families of science as Gastroenterology, Raltegravir, Lamivudine and Raltegravir Potassium. His Viral load research is multidisciplinary, incorporating elements of Endocrinology, Insulin, Regimen, Darunavir and Integrase inhibitor.

The Immunology study combines topics in areas such as Protease inhibitor, Antiretroviral therapy and Intensive care medicine. He combines subjects such as Cohort study, MEDLINE, Viral disease, Pharmacotherapy and Prospective cohort study with his study of Acquired immunodeficiency syndrome. As a part of the same scientific family, José M. Gatell mostly works in the field of Surgery, focusing on Incidence and, on occasion, Bacterial pneumonia, Etiology and Complication.

His most cited work include:

  • Treatment for adult HIV infection : 2006 recommendations of the international AIDS society-USA panel (993 citations)
  • Antiretroviral Therapy in Adults: Updated Recommendations of the International AIDS Society–USA Panel (956 citations)
  • Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection (610 citations)

What are the main themes of his work throughout his whole career to date?

José M. Gatell mostly deals with Internal medicine, Immunology, Viral load, Virology and Acquired immunodeficiency syndrome. His Internal medicine research is multidisciplinary, incorporating perspectives in Gastroenterology, Surgery and Ritonavir. His work deals with themes such as Adverse effect and Stavudine, which intersect with Gastroenterology.

His research in Viral load focuses on subjects like Raltegravir, which are connected to Pharmacology. His Virology research includes elements of Nucleoside Reverse Transcriptase Inhibitor and Antigen. His work in Acquired immunodeficiency syndrome covers topics such as Incidence which are related to areas like Prospective cohort study and Poisson regression.

He most often published in these fields:

  • Internal medicine (48.82%)
  • Immunology (35.43%)
  • Viral load (28.87%)

What were the highlights of his more recent work (between 2013-2021)?

  • Internal medicine (48.82%)
  • Viral load (28.87%)
  • Ritonavir (10.24%)

In recent papers he was focusing on the following fields of study:

His primary areas of study are Internal medicine, Viral load, Ritonavir, Virology and Immunology. His Internal medicine study incorporates themes from Gastroenterology and Emtricitabine. José M. Gatell interconnects Young adult, Viral suppression and Acquired immunodeficiency syndrome in the investigation of issues within Viral load.

José M. Gatell has researched Ritonavir in several fields, including Protease inhibitor, Darunavir, Lopinavir, HIV Protease Inhibitor and Raltegravir. His studies in Virology integrate themes in fields like Treatment outcome and Nucleoside Reverse Transcriptase Inhibitor, Reverse transcriptase, Antiretroviral therapy. His works in Immune system and Immunization are all subjects of inquiry into Immunology.

Between 2013 and 2021, his most popular works were:

  • Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial (113 citations)
  • Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial (108 citations)
  • Beyond viral suppression of HIV – the new quality of life frontier (83 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Acquired immunodeficiency syndrome
  • Immune system

Internal medicine, Immunology, Viral load, Ritonavir and Virology are his primary areas of study. The concepts of his Internal medicine study are interwoven with issues in Dolutegravir and Lamivudine. The various areas that he examines in his Immunology study include Incidence, Drug resistance and Antiretroviral therapy.

His Viral load research is multidisciplinary, relying on both Global health, Acquired immunodeficiency syndrome, Alternative medicine and Hepatitis C virus. His Ritonavir research is multidisciplinary, incorporating elements of Gastroenterology and HIV Protease Inhibitor. His work focuses on many connections between Virology and other disciplines, such as T cell, that overlap with his field of interest in Modified vaccinia Ankara, HIV Antigens, CCL19, Chemokine secretion and Cytokine.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Antiretroviral Therapy in Adults: Updated Recommendations of the International AIDS Society–USA Panel

Charles C. J. Carpenter;David A. Cooper;Margaret A. Fischl;Jose M. Gatell.
JAMA (2000)

1369 Citations

Treatment for adult HIV infection : 2006 recommendations of the international AIDS society-USA panel

Scott M. Hammer;Michael S. Saag;Mauro Schechter;Julio S. G. Montaner.
JAMA (2006)

1109 Citations

Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection

Roy T. Steigbigel;David A. Cooper;Princy N. Kumar;Joseph E. Eron.
The New England Journal of Medicine (2008)

875 Citations

Antiretroviral therapy for HIV infection. A knowledge-based approach to drug selection and use.

Graeme J. Moyle;Brian G. Gazzard;David A. Cooper;José Gatell.
Drugs (1998)

827 Citations

Antiretroviral Treatment of Adult HIV Infection

Scott M. Hammer;Joseph J. Eron;Peter Reiss;Robert T. Schooley.
(2008)

782 Citations

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

Beatriz Grinsztejn;Bach Yen Nguyen;Christine Katlama;Jose M. Gatell.
The Lancet (2007)

773 Citations

Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.

Patrick G. Yeni;Scott M. Hammer;Martin S. Hirsch;Michael S. Saag.
JAMA (2004)

718 Citations

Re-intubation Increases the Risk of Nosocomial Pneumonia in Patients Needing Mechanical Ventilation

A Torres;J M Gatell;E Aznar;M el-Ebiary.
American Journal of Respiratory and Critical Care Medicine (1995)

652 Citations

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.

David A. Cooper;Roy T. Steigbigel;Jose M. Gatell;Jurgen K. Rockstroh.
The New England Journal of Medicine (2008)

587 Citations

Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study

Sean Emery;Jacqueline A. Neuhaus;Andrew N. Phillips;Abdel Babiker.
The Journal of Infectious Diseases (2008)

548 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing José M. Gatell

Jens D. Lundgren

Jens D. Lundgren

Rigshospitalet

Publications: 180

Julio S. G. Montaner

Julio S. G. Montaner

University of British Columbia

Publications: 159

Robert S. Hogg

Robert S. Hogg

Simon Fraser University

Publications: 144

Andrew N. Phillips

Andrew N. Phillips

University College London

Publications: 135

David A. Cooper

David A. Cooper

Pfizer (United States)

Publications: 131

Vincent Soriano

Vincent Soriano

Hospital Universitario La Paz

Publications: 105

Dominique Costagliola

Dominique Costagliola

Université Paris Cité

Publications: 101

Peter Reiss

Peter Reiss

University of Amsterdam

Publications: 100

Caroline Sabin

Caroline Sabin

University College London

Publications: 98

Pere Domingo

Pere Domingo

Autonomous University of Barcelona

Publications: 92

Mark A. Wainberg

Mark A. Wainberg

McGill University

Publications: 92

Amanda Mocroft

Amanda Mocroft

University College London

Publications: 90

Adriano Lazzarin

Adriano Lazzarin

Vita-Salute San Raffaele University

Publications: 89

Bonaventura Clotet

Bonaventura Clotet

University of Vic

Publications: 83

José M. Miró

José M. Miró

University of Barcelona

Publications: 82

Antonella d'Arminio Monforte

Antonella d'Arminio Monforte

University of Milan

Publications: 81

Something went wrong. Please try again later.